@article{f07872128c364158a789783b9df13d91,
title = "Informant-based hearing difficulties and the risk for mild cognitive impairment and dementia",
abstract = "Background: hearing loss has been associated with mild cognitive impairment (MCI) and dementia. Studies have not assessed whether hearing difficulties (HD) that interfere with daily activities as reported by partners can be a marker for increased risk for cognitive decline and impairment. Objective: to assess the cross-sectional and longitudinal associations between informant-based HD, which interfere with daily activities and the risk for MCI and dementia. Methods: the study included 4812 participants without dementia, enrolled in the Mayo Clinic Study of Aging (mean age (SD) 73.7 (9.6) years) with cognitive evaluation and informant-based report on participant's HD that interfere significantly with daily activities at baseline and for every 15 months. Cox proportional hazards models (utilising time-dependent HD status and age as the time scale) were used to examine HD and the risk for MCI or dementia, and mixed-effects models (allowing for random subject-specific intercepts and slopes) were used to examine the relationship between HD and cognitive decline. Results: about, 981 participants had HD and 612 (12.7%) had prevalent MCI at baseline; 759 participants developed incident MCI and 273 developed incident dementia. In cognitively unimpaired participants at baseline, those with HD had higher risk for MCI (hazard ratio [HR] = 1.29, 95% confidence interval [CI] (1.10, 1.51), P = 0.002; adjusting for sex, years of education). In participants without dementia, those with HD had higher risk for dementia (HR: 1.39, 95% CI, (1.08-1.79), P = 0.011; adjusting sex and education). In individuals with MCI, HD was associated with modestly greater cognitive decline. Conclusions: informant-based HD was associated with increased risk for MCI and dementia.",
keywords = "cohort study, dementia, hearing difficulties, mild cognitive impairment, older people",
author = "Maria Vassilaki and Aakre, {Jeremiah A.} and Knopman, {David S.} and Kremers, {Walter K.} and Mielke, {Michelle M.} and Geda, {Yonas E.} and Machulda, {Mary M.} and {Al Fakir}, Razan and Chaitanya Undavalli and Roberts, {Rosebud O.} and Petersen, {Ronald C.}",
note = "Funding Information: Al Fakir, Chaitanya Undavalli, Rosebud Roberts: no conflict of interest. Maria Vassilaki receives research funding from NIH, Roche and Biogen. Walter Kremers receives research funding from the Department of Defense, NIH, Astra Zeneca, Biogen and Roche. Michelle Mielke consults for Eli Lilly, receives unrestricted research grants from Biogen, Lundbeck and Roche and research funding from the National Institute on Aging, NIH and the Department of Defense. Yonas Geda receives funding from the NIH and Roche and serves on the Lundbeck Advisory Board. Mary Machulda receives research funding from the NIH. David Knopman serves on a Data Safety Monitoring Board for the DIAN study; is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen and the Alzheimer{\textquoteright}s Treatment and Research Institute at USC and receives research support from the NIH. Ronald Petersen is a consultant for Roche, Inc., Biogen, Inc., Merck, Inc., Eli Lilly and Company and Genentech, Inc. and receives publishing royalties from MCI (Oxford University Press, 2003) and research support from the NIH. Funding Information: supported by National Institutes of Health (NIH) Grants U01 AG006786, P50 AG016574, R01 AG041851, the GHR Foundation, the Alice Weiner Postdoctoral Research Fellowship in Alzheimer{\textquoteright}s Disease Research, the Mayo Foundation for Medical Education and Research and was made possible by the Rochester Epidemiology Project (R01 AG034676). Funding Information: The study was supported by National Institutes of Health (NIH) Grants U01 AG006786, P50 AG016574, R01 AG041851, the GHR Foundation, the Alice Weiner Postdoctoral Research Fellowship in Alzheimer's Disease Research, the Mayo Foundation for Medical Education and Research and was made possible by the Rochester Epidemiology Project (R01 AG034676). Publisher Copyright: {\textcopyright} 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2019",
month = nov,
day = "1",
doi = "10.1093/ageing/afz099",
language = "English (US)",
volume = "48",
pages = "888--894",
journal = "Age and Ageing",
issn = "0002-0729",
publisher = "Oxford University Press",
number = "6",
}